Home » Newsletters » BioWorld

BioWorld

Oct. 9, 1995

View Archived Issues

SOME BLECH STOCKS SLAMMED IN 1994 CRASH ON REBOUND

BIOTECH FINANCING IN THIRD QUARTER HITS NEW HIGHS

OTHER NEWS TO NOTE

MYRIAD INITIAL PUBLIC OFFERING GENERATES INTEREST, GROSSES $47M

ISIS $25M PUBLIC OFFERING FALLS SHORT OF EXPECTATIONS

BROKERS SEEK $22M IN DAMAGES BLECH UNDER SCRUTINY IN NASD ARBITRATION

BIO LOBBIES SENATE TO RETAIN CAPITAL GAINS TAX BREAK

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.